Abstract
Usually associated with autoimmune diseases, anti-neutrophil cytoplasmic antibodies are also detected in other conditions, such as infections, malignancies, and after intake of certain drugs. Even if the mechanisms of production and their pathogenic role have not been fully elucidated yet, ANCA are widely recognized as a clinically alarming finding due to their association with various disorders. While ANCA target several autoantigens, proteinase-3, and myeloperoxidase are the ones proved to be most frequently related to chronic inflammation and tissue damage in murine models. Albeit these autoantibodies could be present as an isolated observation without any implications, ANCA are frequently used in clinical practice to guide the diagnosis in a suspect of small vessel vasculitis. Conditions that should prompt the clinician to test ANCA status range from various forms of lung disease to renal or peripheral nervous system impairment. ANCA positivity in the presence of an autoimmune disease, especially rheumatoid arthritis, or connective tissue diseases, is frequently correlated with more clinical complications and treatment inefficacy, even in the absence of signs of vasculitis. For this reason, it has been postulated that ANCA could represent the final expression of an immune dysregulation rather than a pathogenic event responsible for organs damage. Recently, it has also been proposed that ANCA specificity (PR3 or MPO) could possibly define ANCA-associated vasculitides better than clinical phenotype. This review aims at summarizing the latest advancements in the field of ANCA study and clinical interpretation.
Similar content being viewed by others
References
Ramponi G, Folci M, De Santis M et al (2021) The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies. Autoimmun Rev 20
Radice A, Sinico RA (2005) Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 38:93–103. https://doi.org/10.1080/08916930400022673
Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, Ferrante M, Flores-Suárez LF, Fritzler MJ, Invernizzi P, Jayne D, Jennette JC, Little MA, McAdoo SP, Novikov P, Pusey CD, Radice A, Salama AD, Savige JA, Segelmark M, Shoenfeld Y, Sinico RA, Sousa MJ, Specks U, Terrier B, Tzioufas AG, Vermeire S, Zhao MH, Bossuyt X (2020) International consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev 19(9):102618. https://doi.org/10.1016/j.autrev.2020.102618. Epub 2020 Jul 12. PMID: 32663621
van Beers JJBC, Vanderlocht J, Roozendaal C, Damoiseaux J (2019) Detection of anti-neutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence. Methods Mol Biol 1901:47–62. https://doi.org/10.1007/978-1-4939-8949-2_4
Suwanchote S, Rachayon M, Rodsaward P et al (2018) Anti-neutrophil cytoplasmic antibodies and their clinical significance. Clin Rheumatol 37:875–884
Bossuyt X, Cohen Tervaert JW, Arimura Y et al (2017) Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13:683–692. https://doi.org/10.1038/nrrheum.2017.140
Damoiseaux J, Csernok E, Rasmussen N et al (2017) Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis 76:647–653. https://doi.org/10.1136/annrheumdis-2016-209507
Csernok E, Damoiseaux J, Rasmussen N et al (2016) Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Autoimmun Rev 15:736–741. https://doi.org/10.1016/J.AUTREV.2016.03.010
Moiseev S, Bossuyt X, Arimura Y et al (2020) International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.202005-1628so
Pendergraft WF, Preston GA, Shah RR et al (2004) Autoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3. Nat Med 10:72–79. https://doi.org/10.1038/nm968
Stegeman CA, Tervaert JW, Sluiter WJ et al (1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120:12–7
Pudifin DJ, Duursma J, Gathiram V, Jackson TF (1994) Invasive amoebiasis is associated with the development of anti-neutrophil cytoplasmic antibody. Clin Exp Immunol 97:48–51
Gilligan HM, Bredy B, Brady HR et al (1996) Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 184:2231–41
Brinkmann V, Reichard U, Goosmann C et al (2004) Neutrophil extracellular traps kill bacteria. Science (80-) 303:1532–1535
Sangaletti S, Tripodo C, Chiodoni C et al (2012) Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 120:3007–3018
Kessenbrock K, Krumbholz M, Schönermarck U et al (2009) Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 15:623–5
Frangou E, Vassilopoulos D, Boletis J, Boumpas DT (2019) An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmun Rev 18:751–760
Valenzuela LM, Draibe JB, Oliveras XF, Matamoros OB, Garrit JM, Ambrós JT (2019) T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach. Clin Kidney J 12(4):503–511. https://doi.org/10.1093/ckj/sfz029
Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA (2006) Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann Rheum Dis 65(11):1484–1489. https://doi.org/10.1136/ard.2005.046219. Epub 2006 Feb 27. PMID: 16504995; PMCID: PMC1798350
Marinaki S, Neumann I, Kalsch A-I et al (2005) Abnormalities of CD4+ T cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol 140:181–191. https://doi.org/10.1111/j.1365-2249.2005.02731.x
Abdulahad WH, Stegeman CA, Kallenberg CG (2009) Review article: The role of CD4(+) T cells in ANC Aassociated systemic vasculitis. Nephrology (Carlton) 14(1):26–32. https://doi.org/10.1111/j.1440-1797.2008.01069.x. Epub 2009 Jan 8. PMID: 19143940
Yoshida M, Iwahori T, Nakabayashi I, Akashi M, Watanabe T, Yoshikawa N (2005) In vitro production of myeloperoxidase anti-neutrophil cytoplasmic antibody and establishment of Th1-type T cell lines from peripheral blood lymphocytes of patients. Clin Exp Rheumatol 23(2):227–230. PMID: 15895894
Abdulahad WH, Lepse N, Stegeman CA, Huitema MG, Doornbos-van der Meer B, Tadema H, Rutgers A, Limburg PC, Kallenberg CG, Heeringa P (2013) Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA). Arthritis Res Ther 15(3):R70. https://doi.org/10.1186/ar4247. PMID: 23799890; PMCID: PMC4060544
Ruth AJ, Kitching AR, Kwan RY, Odobasic D, Ooi JD, Timoshanko JR, Hickey MJ, Holdsworth SR (2006) Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. J Am Soc Nephrol 17(7):1940–1949. https://doi.org/10.1681/ASN.2006020108. Epub 2006 Jun 12. PMID: 16769746
Hagen EC, de Keizer RJ, Andrassy K, van Boven WP, Bruijn JA, van Es LA, van der Woude FJ (1995) Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 43(6):351–359. PMID: 7554518
Xiao H, Schreiber A, Heeringa P et al (2007) Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170:52–64
Gómez-Puerta JA, Bosch X (2009) Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am J Pathol 175:1790–1798. https://doi.org/10.2353/ajpath.2009.090533
Berglin E, Mohammad AJ, Dahlqvist J et al (2021) Anti-neutrophil cytoplasmic antibodies predate symptom onset of ANCA-associated vasculitis A case-control study. J Autoimmun 117. https://doi.org/10.1016/j.jaut.2020.102579
Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606. https://doi.org/10.1007/s10157-013-0869-6
Robson JC, Grayson PC, Ponte C et al (2018) OP0021 Draft classification criteria for the ANCA associated vasculitides. In: Wednesday, 13 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism 60.2–61
Robson J, Grayson P, Ponte C et al (2019) Classification criteria for the ANCA-associated vasculitides. Rheumatology 58. https://doi.org/10.1093/rheumatology/kez058.050
Seeliger B, Sznajd J, Robson JC et al (2017) Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology 56:1154–1161. https://doi.org/10.1093/rheumatology/kex075
Comarmond C, Cacoub P (2014) Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev 13:1121–1125. https://doi.org/10.1016/j.autrev.2014.08.017
Trimarchi M, Sinico RA, Teggi R et al (2013) Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener’s). Autoimmun Rev 12:501–505. https://doi.org/10.1016/j.autrev.2012.08.010
Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–98
Girard C, Charles P, Terrier B et al (2015) Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegenerʼs). Medicine (Baltimore) 94:e1088. https://doi.org/10.1097/MD.0000000000001088
Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043. https://doi.org/10.1136/ard.2009.109389
Chang D, Wu L, Liu G et al (2012) Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant 27:2343–2349. https://doi.org/10.1093/ndt/gfr643
Dufour J-F, Le Gallou T, Cordier J-F et al (2012) Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. Medicine (Baltimore) 91:67–74. https://doi.org/10.1097/MD.0b013e318239add6
Seror R, Mahr A, Ramanoelina J et al (2006) Central nervous system involvement in Wegener granulomatosis. Medicine (Baltimore) 85:53–65. https://doi.org/10.1097/01.md.0000200166.90373.41
Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA (1983) Ocular complications of Wegener’s granulomatosis. Ophthalmology 90:279–290
Perry SR, Rootman J, White VA (1997) The clinical and pathologic constellation of Wegener granulomatosis of the orbit. Ophthalmology 104:683–694
Korantzopoulos P, Papaioannides D, Siogas K (2004) The heart in Wegener’s granulomatosis. Cardiology 102:7–10. https://doi.org/10.1159/000076995
Deniz K, Ozşeker HS, Balas S et al (2007) Intestinal involvement in Wegener’s granulomatosis. J Gastrointestin Liver Dis 16:329–331
Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430. https://doi.org/10.1002/1529-0131(199904)42:3%3c421::AID-ANR5%3e3.0.CO;2-6
Finkielman JD, Lee AS, Hummel AM et al (2007) ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med 120. https://doi.org/10.1016/j.amjmed.2006.08.016
Kitching AR, Anders HJ, Basu N et al (2020) ANCA-associated vasculitis. Nat Rev Dis Prim 6
Hagen EC, Daha MR, Hermans J et al (1998) Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 53. https://doi.org/10.1046/j.1523-1755.1998.00807.x
Jennette JC, Wilkman AS, Falk RJ (1998) Diagnostic predictive value of ANCA serology. Kidney Int 53
Villiger PM, Guillevin L (2010) Microscopic polyangiitis: clinical presentation. Autoimmun Rev 9:812–819. https://doi.org/10.1016/j.autrev.2010.07.009
Lauque D, Cadranel J, Lazor R et al (2000) Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d’Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 79:222–33
Schirmer JH, Wright MN, Vonthein R et al (2016) Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology 55:71–79. https://doi.org/10.1093/rheumatology/kev286
Alba MA, Flores-Suárez LF, Henderson AG et al (2017) Interstital lung disease in ANCA vasculitis. Autoimmun Rev 16
Zhang W, Zhou G, Shi Q, Zhang X, Zeng XF, Zhang FC (2009) Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 27(1 Suppl 52):S65–S69. PMID: 19646349
Niiyama S, Amoh Y, Tomita M, Katsuoka K (2008) Dermatological manifestations associated with microscopic polyangiitis. Rheumatol Int 28:593–595. https://doi.org/10.1007/s00296-007-0497-0
Bacciu A, Bacciu S, Mercante G et al (2006) Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 126:503–509. https://doi.org/10.1080/00016480500437435
Keogh K, Specks U (2006) Churg-Strauss syndrome. Semin Respir Crit Care Med 27:148–157. https://doi.org/10.1055/s-2006-939518
Dennert RM, Van Paassen P, Schalla S et al (2010) Cardiac involvement in churg-strauss syndrome. Arthritis Rheum 62:627–634
Cattaneo L, Chierici E, Pavone L et al (2007) Peripheral neuropathy in Wegener’s granulomatosis, Churg Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry 78:1119–1123. https://doi.org/10.1136/jnnp.2006.111013
Vaglio A, Buzio C, Zwerina J (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy 68:261–273. https://doi.org/10.1111/all.12088
Sinico RA, Di Toma L, Maggiore U et al (2006) Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 47:770–779. https://doi.org/10.1053/j.ajkd.2006.01.026
Sablé-Fourtassou R, Cohen P, Mahr A et al (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143:632–638
Comarmond C, Pagnoux C, Khellaf M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270–281
Moosig F, Bremer JP, Hellmich B et al (2013) A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 72. https://doi.org/10.1136/annrheumdis-2012-201531
Groh M, Pagnoux C, Baldini C et al (2015) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26. https://doi.org/10.1016/j.ejim.2015.04.022
Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715
Windpessl M, Bettac EL, Gauckler P et al (2021) ANCA Status or clinical phenotype — what counts more? Curr Rheumatol Rep 23
Hakroush S, Kluge IA, Ströbel P et al (2021) Systematic histological scoring reveals more prominent interstitial inflammation in myeloperoxidase-ANCA compared to proteinase 3-ANCA glomerulonephritis. J Clin Med 10:1231. https://doi.org/10.3390/jcm10061231
Wu T, Shen C, Zhong Y et al (2021) Differences between myeloperoxidase-antineutrophil cytoplasmic autoantibody (ANCA) and proteinase 3-ANCA associated vasculitis: a retrospective study from a single center in China. Exp Ther Med 21. https://doi.org/10.3892/etm.2021.9993
Hilhorst M, van Paassen P, Tervaert JWC, Registry Limburg Renal (2015) Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol 26:2314–2327. https://doi.org/10.1681/ASN.2014090903
Geetha D, Specks U, Stone JH et al (2015) Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 26:976–985
Wallace ZS, Stone JH (2019) Personalized medicine in ANCA-associated vasculitis ANCA specificity as the guide? Front Immunol 10:2855
Vernier G, Sendid B, Poulain D, Colombel JF (2004) Relevance of serologic studies in inflammatory bowel disease. Curr. Gastroenterol. Rep. 6:482–487
Olsson R, Daniels Son A, Jarnerot G et al (1991) Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis
Hardarson S, Labrecqu DR, Mitros FA et al (1993) Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases: high prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis. Am J Clin Pathol 99:277–281. https://doi.org/10.1093/ajcp/99.3.277
Peen E, Almer S, Bodemar G et al (1993) Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease. Gut 34:56–62. https://doi.org/10.1136/gut.34.1.56
Aadland E, Schrumpf E, Fausa O et al (1987) Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 22:655–664. https://doi.org/10.3109/00365528709011139
Nisihara RM, De Carvalho WB, Da Rosa Utiyama SR et al (2010) Diagnostic role and clinical association of ASCA and ANCA in Brazilian patients with inflammatory bowel disease. Dig Dis Sci 55:2309–2315. https://doi.org/10.1007/s10620-009-0998-7
Saibeni S, Folli C, de Franchis R et al (2003) Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis 35:862–868. https://doi.org/10.1016/j.dld.2003.07.001
Damoiseaux JGMC, Bouten B, Linders AMLW et al (2002) Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J Clin Immunol 22:281–288. https://doi.org/10.1023/A:1019926121972
Quinton J-F, Sendid B, Reumaux D et al (1998) Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42:788–791. https://doi.org/10.1136/gut.42.6.788
Prideaux L, De Cruz P, Ng SC, Kamm MA (2012) Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 18:1340–1355
Maaser C, Sturm A, Vavricka SR et al (2019) ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn’s Colitis 13:144–164. https://doi.org/10.1093/ecco-jcc/jjy113
Lee WI, Subramaniam K, Hawkins CA, Randall KL (2019) The significance of ANCA positivity in patients with inflammatory bowel disease. Pathology 51:634–639. https://doi.org/10.1016/j.pathol.2019.07.002
Thurgate LE, Lemberg DA, Day AS, Leach ST (2019) An overview of inflammatory bowel disease unclassified in children. Inflamm Intest Dis 4:97–103. https://doi.org/10.1159/000501519
Horn MP, Peter AM, Grunder FR et al (2018) PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn’s disease PLoS One 13. https://doi.org/10.1371/journal.pone.0208974
Tremaine WJ (2011) Diagnosis and treatment of indeterminate colitis. Gastroenterol Hepatol (N Y) 7:826–828
Bossuyt X (2005) Serologic markers in inflammatory bowel disease. Clin Chem 52:171–181. https://doi.org/10.1373/clinchem.2005.058560
Birimberg-Schwartz L, Wilson DC, Kolho KL et al (2016) PANCA and ASCA in children with IBD-unclassified, Crohn’s colitis, and ulcerative colitis - a longitudinal report from the IBD Porto Group of ESPGHAN. Inflamm Bowel Dis 22:1908–1914. https://doi.org/10.1097/MIB.0000000000000784
Arias-Loste MT, Bonilla G, Moraleja I et al (2013) Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (Anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 45:109–116. https://doi.org/10.1007/s12016-012-8349-4
Mahler M, Bogdanos DP, Pavlidis P et al (2013) PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta 424:267–273. https://doi.org/10.1016/j.cca.2013.06.005
Van Biervliet S, Bonroy C, Vande Velde S et al (2013) C-ANCA/proteinase 3-positive colitis in children: a distinctive form of inflammatory bowel disease or vasculitis with colitis as initial presentation? J Pediatr Gastroenterol Nutr 57:489–492. https://doi.org/10.1097/MPG.0b013e31829d4e9e
Stinton L, Kaplan G, Mahler M et al (2013) Proteinase 3 (PR3) autoantibodies as a serological marker in inflammatory bowel disease (IBD). Am J Gastroenterol
Stinton LM, Bentow C, Mahler M et al (2014) PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). PLoS One 9:e112877. https://doi.org/10.1371/journal.pone.0112877
Mahler M, Damoiseaux J, Ballet V et al (2017) PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis. Clin Chem Lab Med 56:e27–e30
Takedatsu H, Mitsuyama K, Fukunaga S et al (2018) Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol 33:1603–1607. https://doi.org/10.1111/jgh.14140
Trivedi PJ, Hubscher SG, Heneghan M et al (2019) Grand round: autoimmune hepatitis. J Hepatol 70:773–784. https://doi.org/10.1016/j.jhep.2018.11.006
Lohse AW, Chazouillères O, Dalekos G et al (2015) EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 63:971–1004. https://doi.org/10.1016/j.jhep.2015.06.030
Toda G, Zeniya M (1993) Autoimmune hepatitis. Intern Med 32:913–916
Mulder AHL, Horst G, Haagsma EB et al (1993) Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 17:411–417. https://doi.org/10.1002/hep.1840170310
Zauli D, Ghetti S, Grassi A et al (1997) Anti-neutrophilcytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25:1105–1107. https://doi.org/10.1002/hep.510250510
Targan SR, Landers C, Vidrich A, Czaja AJ (1995) High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 108:1159–1166. https://doi.org/10.1016/0016-5085(95)90215-5
Vergani D, Alvarez F, Bianchi FB et al (2004) Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 41:677–683
Terjung B, Spengler U, Sauerbruch T, Worman HJ (2000) “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119:310–322. https://doi.org/10.1053/gast.2000.9366
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D (2018) Serology in autoimmune hepatitis: a clinical-practice approach. Eur J Intern Med 48:35–43. https://doi.org/10.1016/j.ejim.2017.10.006
Nicoletti A, Maurice JB, Thorburn D (2021) Guideline review: British Society of Gastroenterology/UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Front Gastroenterol 12:62–66
Terjung B, Spengler U (2005) Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol 28:115–133
Lo SK, Fleming KA, Chapman RW (1994) A 2-year follow-up study of anti-neutrophil antibody in primary sclerosing cholangitis: relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment. J Hepatol 21:974–978. https://doi.org/10.1016/S0168-8278(05)80604-X
Hov JR, Boberg KM, Taraldsrud E et al (2017) Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis. Liver Int 37:458–465. https://doi.org/10.1111/liv.13238
Wunsch E, Norman GL, Milkiewicz M et al (2021) Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther 53:302–313. https://doi.org/10.1111/apt.16153
Borchers AT, Leibushor N, Naguwa SM et al (2012) Lupus nephritis: a critical review. Autoimmun Rev 12:174–194
Sen D, Isenberg DA (2003) Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 12:651–658
Barile-Fabris L, Hernández-Cabrera MF, Barragan-Garfias JA (2014) Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep 16. https://doi.org/10.1007/s11926-014-0440-9
Mirza R, Urowitz M, Su J GD (2020) ANCA in SLE: prevalence and predictor factors - ACR meeting abstracts. In Arthritis Rheumatol. https://acrabstracts.org/abstract/anca-in-sle-prevalence-and-predictor-factors/
Wang Y, Huang X, Cai J et al (2016) Clinicopathologic characteristics and outcomes of lupus nephritis with antineutrophil cytoplasmic antibody: a retrospective study. Medicine (United States) 95. https://doi.org/10.1097/MD.0000000000002580
Manolova I, Dancheva M, Halacheva K (2001) Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. Rheumatol Int 20:197–204. https://doi.org/10.1007/s002960100108
Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, De Ramòn Garrido E, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Mathieu A, Papasteriades C, Piette JC, Scorza R, Smolen J (1998) Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol 16(5):541–546. PMID: 9779300
Ramaswami A, Kandaswamy T, Rajendran T et al (2008) Scleroderma with crescentic glomerulonephritis: a case report. J Med Case Rep 2. https://doi.org/10.1186/1752-1947-2-151
Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117
Shanmugam VK, Steen VD (2012) Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol 24
Chung L, Utz PJ (2004) Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep 6:156–163
Caramaschi P, Biasi D, Tonolli E et al (2002) Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature. Jt Bone Spine 69:177–180. https://doi.org/10.1016/S1297-319X(02)00367-6
Quéméneur T, Mouthon L, Cacoub P et al (2013) Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine (United States) 92:1–9
Moxey J, Huq M, Proudman S et al (2019) Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. Arthritis Res Ther 21:1–12. https://doi.org/10.1186/s13075-019-1839-5
Derrett-Smith EC, Nihtyanova SI, Harvey J et al (2013) Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (United Kingdom) 52:1824–1831. https://doi.org/10.1093/rheumatology/ket213
Arad U, Balbir-Gurman A, Doenyas-Barak K et al (2011) Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum 41. https://doi.org/10.1016/j.semarthrit.2010.11.001
Young HR, Seong JC, Young HL et al (2006) Scleroderma associated with ANCA-associated vasculitis. Rheumatol Int 26
Liang KP, Michet CJ (2011) ANCA-associated vasculitis in scleroderma: a case series of fourteen patients. Rheumatol Rep 3
Brito-Zerón P, Baldini C, Bootsma H et al (2016) Sjögren syndrome. Nat Rev Dis Prim 2:1–20. https://doi.org/10.1038/nrdp.2016.47
Fayyaz A, Kurien BT, Scofield RH (2016) Autoantibodies in Sjögren’s syndrome. Rheum Dis Clin North Am 42
Ramos-Casals M, Nardi N, Brito-Zerón P et al (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35. https://doi.org/10.1016/j.semarthrit.2005.12.004
Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87. https://doi.org/10.1097/MD.0b013e318181e6af
Specks U, Wiegert EM, Homburger HA (1997) Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 109. https://doi.org/10.1046/j.1365-2249.1997.4561353.x
Noel N, André C, Bengoufa D et al (2013) Performance evaluation of three assays for the detection of PR3-ANCA in granulomatosis with polyangiitis in daily practice. Autoimmun Rev 12
Lee IH, Kim SK, Kim MK (2016) Dual anti-neutrophil cytoplasmic antibody-related pauci-immune crescentic glomerulonephritis in a patient with Sjögren’s syndrome. Rheumatol Int 36
Morimoto C, Fujigaki Y Tamura Y et al (2018) Emergence of smoldering ANCA-associated glomerulonephritis during the clinical course of mixed connective tissue disease and sjögren’s syndrome. Intern Med 57. https://doi.org/10.2169/internalmedicine.9844-17
Hsu CW, Su YJ, Chang WN et al (2014) The association between serological biomarkers and primary Sjogren’s syndrome associated with peripheral polyneuropathy. Biomed Res Int 2014. https://doi.org/10.1155/2014/902492
Guellec D, Cornec-Le Gall E, Groh M et al (2015) ANCA-associated vasculitis in patients with primary Sjögren’s syndrome: detailed analysis of 7 new cases and systematic literature review. Autoimmun Rev 14
Lee S, Bin H, Choi MK, Kim et al (2020) Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren’s syndrome? Rheumatol Int 40 https://doi.org/10.1007/s00296-019-04476-5
Font J, Ramos-Casals M, Cervera R et al (1998) Antineutrophil cytoplasmic antibodies in primary Sjogren’s syndrome: prevalence and clinical significance. Br J Rheumatol 37. https://doi.org/10.1093/rheumatology/37.12.1287
Stone JH, Zen Y, Deshpande V (2012) Mechanisms of disease: IgG4-related disease. N Engl J Med 366. https://doi.org/10.1056/NEJMra1104650
Maritati F, Peyronel F, Vaglio A (2020) IgG4-related disease: a clinical perspective. Rheumatology (United Kingdom) 59
Lin W, Lu S, Chen H et al (2015) Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatology (United Kingdom) 54. https://doi.org/10.1093/rheumatology/kev203
Umehara H, Okazaki K, Masaki Y et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22. https://doi.org/10.1007/s10165-011-0571-z
Carruthers MN, Khosroshahi A, Augustin T et al (2015) The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 74. https://doi.org/10.1136/annrheumdis-2013-204907
Sekiguchi H, Horie R, Kanai M et al (2016) IgG4-related disease: retrospective analysis of one hundred sixty-six patients. Arthritis Rheumatol 68. https://doi.org/10.1002/art.39686
Erden A, Bolek EC, Yardimci KG et al (2019) Do ANCA-associated vasculitides and IgG4-related disease really overlap or not? Int J Rheum Dis 22. https://doi.org/10.1111/1756-185X.13693
Martín-Nares E, Zuñiga-Tamayo D, Hinojosa-Azaola A (2019) Prevalence of overlap of antineutrophil cytoplasmic antibody associated vasculitis with systemic autoimmune diseases: an unrecognized example of poliautoimmunity. Clin Rheumatol 38. https://doi.org/10.1007/s10067-018-4212-1
Detlefsen S, Vos De JD, Tanassi JT et al (2018) Value of anti-plasminogen binding peptide, anticarbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune pancreatitis and pancreatic cancer. Medicine (United States) 97. https://doi.org/10.1097/MD.0000000000011641
Mustila A, Paimela L, Leirisalo-Repo M et al (2000) Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: an early marker of progressive erosive disease. Arthritis Rheum 43. https://doi.org/10.1002/1529-0131(200006)43:6/1371::AID-ANR22/3.0.CO;2-R
Braun MG, Csernok E, Schmitt WH, Gross WL (1996) Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. J Rheumatol 23
Mandl LA, Solomon DH, Smith EL et al (2002) Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med 162. https://doi.org/10.1001/archinte.162.13.1509
Mustila A, Korpel M, Mustonen J et al (1997) Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy. 40:710–717
Voskuyl AE, Hazes JMW, Zwinderman AH et al (2003) Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 62. https://doi.org/10.1136/ard.62.5.407
Kida I, Kobayashi S, Takeuchi K et al (2011) Antineutrophil cytoplasmic antibodies against myeloperoxidase, proteinase 3, elastase, cathepsin G and lactoferrin in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21. https://doi.org/10.1007/s10165-010-0356-9
Bosch X, Llena J, Collado A et al (1995) Occurrence of antineutrophil cytoplasmic and antineutrophil (peri)nuclear antibodies in rheumatoid arthritis. J Rheumatol 22
Chinoy H, McKenna F (2002) Wegener’s granulomatosis and rheumatoid arthritis overlap [3]. Rheumatology 41
Pagnoux C, Seror R, Bérezné A et al (2010) Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. Jt Bone Spine 77. https://doi.org/10.1016/j.jbspin.2010.02.013
Röther E, Schochat T, Peter HH (1996) Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study. Rheumatol Int 15. https://doi.org/10.1007/BF00290376
Ramos-Casals M, Brito-Zerón P, Soto MJ et al (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22
Spoerl D, Pers YM, Jorgensen C (2012) Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: two case reports and review of literature. Allergy Asthma Clin Immunol 8. https://doi.org/10.1186/1710-1492-8-19
Ramos-Casals M, Jara LJ, Medina F et al (2005) Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med 257. https://doi.org/10.1111/j.1365-2796.2005.01490.x
Asherson RA, Cervera R (2003) Antiphospholipid antibodies and infections. Ann Rheum Dis 62
Choi HK, Lamprecht P, Niles JL et al (2000) Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 43. https://doi.org/10.1002/1529-0131(200001)43:1/226::AID-ANR27/3.0.CO;2-Q
Davies DJ, Moran JE, Niall JF, Ryan GB (1982) Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 285(6342):606. https://doi.org/10.1136/bmj.285.6342.606. PMID: 6297657; PMCID: PMC1499415
Guillevin L, Lhote F, Ghérardi R (1997) The spectrum and treatment of virus-associated vasculitides. Curr Opin Rheumatol 9
Schmitt WH, Van Der Woude FJ (2004) Clinical applications of antineutrophil cytoplasmic antibody testing. Curr Opin Rheumatol 16
Zeledon JI, McKelvey RL, Servilla KS et al (2008) Glomerulonephritis causing acute renal failure during the course of bacterial infections. Histological varieties, potential pathogenetic pathways and treatment. Int Urol Nephrol 40. https://doi.org/10.1007/s11255-007-9323-6
Wu YY, Hsu TC, Chen TY et al (2002) Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection. Clin Exp Immunol 128. https://doi.org/10.1046/j.1365-2249.2002.01827.x
Chou TN, Hsu TC, Chen RM et al (2000) Parvovirus B19 infection associated with the production of anti-neutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibody (aCL). Lupus 9:551–554. https://doi.org/10.1177/096120330000900714
Chan B, d’Intini V, Savige J (2006) Anti-neutrophil cytoplasmic antibody (ANCA)-associated microscopic polyangiitis following a suppurative wound infection [8]. Nephrol Dial Transplant 21
Papayannopoulos V, Zychlinsky A (2009) NETs: a new strategy for using old weapons. Trends Immunol 30
Popa ER, Stegeman CA, Abdulahad WH et al (2007) Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener’s granulomatosis. Rheumatology 46 https://doi.org/10.1093/rheumatology/kem022
Kallenberg CGM, Tadema H (2008) Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to “autoimmunity and infection.” Autoimmun Rev 8
Tidman M, Olander R, Svalander C, Danielsson D (1998) Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975–95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 244. https://doi.org/10.1046/j.1365-2796.1998.00324.x
Nässberger L, Johansson A-C, Björck S, Sjöholm AG (1991) Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment. J Intern Med 229. https://doi.org/10.1111/j.1365-2796.1991.tb00342.x
Almroth G, Eneström S Hed J et al (1992) Autoantibodies to leucocyte antigens in hydralazine-associated nephritis. J Intern Med 231. https://doi.org/10.1111/j.1365-2796.1992.tb00496.x
StokesMB, Foster K, Markowitz GS et al (2005) Development of glomerulonephritis during anti-TNF-alpha; therapy for rheumatoid arthritis. Nephrol Dial Transplant 20. https://doi.org/10.1093/ndt/gfh832
Simms R, Kipgen D, Dahill S et al (2008) ANCA-associated renal vasculitis following anti-tumor necrosis factor α therapy. Am J Kidney Dis 51. https://doi.org/10.1053/j.ajkd.2007.10.043
Bienaimé F, Clerbaux G, Plaisier E et al (2007) d-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. Am J Kidney Dis 50. https://doi.org/10.1053/j.ajkd.2007.05.026
Locke IC, Worrall JG, Leaker B et al (1997) Autoantibodies to myeloperoxidase in systemic sclerosis. J Rheumatol 24
Salerno SM, Ormseth EJ, Roth BJ et al (1996) Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener’s granulomatosis. Chest 110. https://doi.org/10.1378/chest.110.2.556
Denissen NHAM, Peters JGP, Masereeuw R, Barrera P (2008) Can sulfasalazine therapy induce or exacerbate Wegener’s granulomatosis? Scand J Rheumatol 37. https://doi.org/10.1080/03009740701607117
Sethi S, Sahani M, Oei LS (2003) ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. Am J Kidney Dis 42. https://doi.org/10.1016/s0272-6386(03)00671-1
Gao Y, Zhao MH, Guo XH et al (2004) The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res 30. https://doi.org/10.1081/ERC-120037729
Cambridge G, Wallace H, Bernstein RM, Leaker B (1994) Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Rheumatology 33. https://doi.org/10.1093/rheumatology/33.2.109
Gao Y, Chen M, Ye H et al (2007) The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil. Int Immunopharmacol 7. https://doi.org/10.1016/j.intimp.2006.07.033
Chen YX, Yu HJ, Ni LY et al (2007) Propylthiouracil-associated antineutrophil cytoplasmic autoantibody- positive vasculitis: Retrospective study of 19 cases. J Rheumatol 34
Martin DB, Deng A, Gaspari A, Pearson F (2006) Perinuclear antineutrophil cytoplasmic antibody-associated vasculitis in a patient with Graves’ disease treated with methimazole. Skinmed 5. https://doi.org/10.1111/j.1540-9740.2006.05350.x
Calañas-Continente A, Espinosa M, Manzano-García G et al (2005) Necrotizing glomerulonephritis and pulmonary hemorrhage associated with carbimazole therapy. Thyroid 15. https://doi.org/10.1089/thy.2005.15.286
Hachicha M, Kammoun T, Romdhane WB et al (2007) Vasculitis with renal involvement andantineutrophil cytoplasmic antibodies (ANCA) inachild receiving benzylthiouracil. Nephrol Ther 3. https://doi.org/10.1016/j.nephro.2007.04.001
Gao Y, Ye H, Yu F et al (2005) Anti-myeloperoxidase IgG subclass distribution and avidity in sera from patients with propylthiouracil-induced antineutrophil cytoplasmic antibodies associated vasculitis. Clin Immunol 117. https://doi.org/10.1016/j.clim.2005.06.002
Schroeder JW, Folci M, Losappio LM et al (2019) Anti-neutrophil cytoplasmic antibodies positivity and anti-leukotrienes in eosinophilic granulomatosis with polyangiitis: a retrospective monocentric study on 134 Italian patients. Int Arch Allergy Immunol 180:64–71
Graf J (2013) Rheumatic manifestations of cocaine use. Curr Opin Rheumatol 25
Trimarchi M, Bussi M, Sinico RA et al (2013) Cocaine-induced midline destructive lesions - an autoimmune disease? Autoimmun Rev 12:496–500
McGrath MM, Isakova T, Rennke HG et al (2011) Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol 6:2799–2805. https://doi.org/10.2215/CJN.03440411
Orriols R, Muñoz X, Ferrer J et al (1996) Cocaine-induced Churg-Strauss vasculitis. Eur Respir J 9. https://doi.org/10.1183/09031936.96.09010175
Pendergraft WF, Niles JL (2014) Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 26
Choi HK, Merkel PA, Walker AM, Niles JL (2000) Drug-associated antineutrophil cytoplasmic antibody–positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43:405. https://doi.org/10.1002/1529-0131(200002)43:2%3c405::AID-ANR22%3e3.0.CO;2-5
Racanelli V, Prete M, Minoia C et al (2008) Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 7:352–358
Hamidou MA, El Kouri D, Audrain M, Grolleau JY (2001) Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. Ann Rheum Dis 60:293–295
Miyata KN, Siddiqi NA, Kiss LP et al (2017) Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. Clin Nephrol Case Stud 5:9–15
Wills Sanín B, Bolivar YRC, Carvajal JJ et al (2014) Polyangiitis with granulomatosis as a paraneoplastic syndrome of B-cell lymphoma of the lacrimal gland. Case Rep Hematol 2014:713048
Tamoto Y, Ishida R, Shiogama K et al (2017) Extranodal NK/T-cell lymphoma, nasal type accompanied by PR3-ANCA-associated glomerulonephritis. Intern Med 56:2007–2012
Jayachandran NV, Thomas J, Chandrasekhara PKS et al (2009) Cutaneous vasculitis as a presenting manifestation of acute myeloid leukemia. Int J Rheum Dis 12:70–73
Philipponnet C, Garrouste C, Le Guenno G et al (2017) Antineutrophilic cytoplasmic antibody-associated vasculitis and malignant hemopathies, a retrospective study of 16 cases. Joint Bone Spine 84:51–57
Folci M, Ramponi G, Shiffer D et al (2019) ANCA-associated vasculitides and hematologic malignancies: lessons from the past and future perspectives. J Immunol Res 2019:1–9. https://doi.org/10.1155/2019/1732175
Godbole MS, Valenzuela R, Deodhar SD et al (1995) Comparative study of ELISA and indirect immunofluorescence for the detection of anti-neutrophil cytoplasmic antibodies. Evaluation of the SCIMEDX/EURO Diagnostica ELISA assay in a clinical setting. Am J Clin Pathol 104:667–672
Shang W, Ning Y, Xu X et al (2015) Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One 10:e0126016
Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ (2015) Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer 15:201–15
Dengler R, Münstermann U, al-Batran S et al (1995) Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 89:250–7
Ye B, Stary CM, Gao Q et al (2017) Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies. J Immunol Res 2017:1–13
Qazilbash MH, Wieder E, Thall PF et al (2017) PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31:697–704
Sergeeva A, Alatrash G, He H et al (2011) An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 117:4262–72
Alatrash G, Molldrem JJ, Qazilbas MH (2018) Targeting PR1 in myeloid leukemia. Oncotarget 9:4280–4281
Grönwall C, Silverman GJ (2014) Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J Clin Immunol 34
Lacroix-Desmazes S, Kaveri SV, Mouthon L et al (1998) Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216. https://doi.org/10.1016/S0022-1759(98)00074-X
Cui Z, Zhao M-H, Segelmark M, Hellmark T (2010) Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 78:590–597. https://doi.org/10.1038/ki.2010.198
Jeffs L, Peh C, Nelson A et al (2019) IgM ANCA in healthy individuals and in patients with ANCA-associated vasculitis. Immunol Res 67. https://doi.org/10.1007/s12026-019-09091-x
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Folci, M., Ramponi, G., Solitano, V. et al. Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis. Clinic Rev Allerg Immunol 63, 107–123 (2022). https://doi.org/10.1007/s12016-021-08887-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-021-08887-w